Eli Lilly’s COVID-19 Antibody Treatment Closes In on the Goal
Eli Lilly shares made a handy gain on Wednesday after the company announced an update to its SARS-CoV-2 neutralizing antibody programs.
All Work
Chris Lange
How Levi Strauss Managed a Big Q3 Win Despite COVID-19 Headwinds
Levi Strauss shares rallied Wednesday morning after the clothing company reported better than expected fiscal third-quarter financial results late Thursday.
Why Investors Have to Be Happy With Alexion’s Latest Update
Announcements that Alexion Pharmaceuticals made at its virtual Investor Day about expanding its pipeline and its guidance led to a handy gain in its shares on Tuesday.
Vir Biotechnology Expands Its Late-Stage COVID-19 Study
Vir Biotechnology shares jumped on Tuesday after the firm announced that it would be expanding its late-stage COVID-19 study in conjunction with GlaxoSmithKline.
DraftKings Is Back At The Table With Another Secondary Offering
DraftKings Inc. (NASDAQ: DKNG | DKNG Price Prediction) shares slid on Monday after it was announced that the online gaming firm would be conducting a secondary offering. Now seems to be as good a…
ImmunoGen Sees Solid Win With FDA Update
ImmunoGen shares pushed higher to start out the week when the FDA provided an update for the firm’s treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.
How Nvidia Is Fighting Disease With AI
Nvidia has announced it will partner with GlaxoSmithKline to apply its artificial intelligence and supercomputers for the drug and vaccine discovery process.
Corvus Shareholders Must Be Happy With This COVID-19 Study Update
Corvus Pharmaceuticals shares were sharply higher on Monday after the company announced updated data from its ongoing early-stage study in patients with COVID-19.
MyoKardia Shareholders Are Getting a Really Sweet Payday
MyoKardia shares hit an all-time high early on Monday after it was announced that Bristol-Myers Squibb would be acquiring the company.
Where We Stand on a Vaccine After Trump Catches COVID-19
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
How Playboy Aims to Come Public Again
Mountain Crest Acquisition, a special purpose acquisition company has decided to return Playboy to the public markets.
Should Dick’s Still Be Increasing the Number of Its Stores?
Retailers have been hit hard during the pandemic, and many have shut their brick-and-mortar locations. However, Dick’s Sporting Goods is expanding its nationwide footprint.
Why Solid Bio’s Future Just Got a Lot Brighter
Solid Biosciences shares more than doubled on Thursday after the company announced a key update from the FDA.
Why the Bed Bath & Beyond Turnaround Finally Has Come True
Bed Bath & Beyond reported better than expected fiscal second-quarter financial results before the markets opened on Thursday.
Did Palantir’s Market Debut Live Up to the Hype?
Sofftware platform maker Palantir Technologies came public Wednesday through a direct listing that valued the company at about $22 billion.
Why Analysts Are Cautiously Optimistic About Micron After Earnings
Although investors were disappointed with the Micron Technology quarterly results, analysts looked further out and were fairly positive.
Why Pizza Giants Will Keep Thriving After the Pandemic
The name of the game for restaurants during the government-mandated COVID-19 lockdowns has been delivery, and nobody does that better than pizza companies.
2 Big Positive Developments in the COVID-19 Vaccine Race
Moderna and Regeneron Pharmaceuticals each announced positive news late on Tuesday about their respective COVID-19 vaccine trials.
Beyond Meat’s Distribution Expansion With Walmart Is Only Natural
Beyond Meat shares hit a multiyear high on Tuesday after the company announced that it would expand its long-standing relationship with Walmart.
Why Aptorum Stock Absolutely Took Off on Tuesday
Aptorum shares absolutely exploded on Tuesday after the company announced that it would be launching a subsidiary focused on novel technologies targeting infectious diseases.